Pięć najczęstszych złośliwych nowotworów psów w praktyce weterynaryjnej - Vetkompleksowo – serwis dla lekarzy weterynarii

Pięć najczęstszych złośliwych nowotworów psów w praktyce weterynaryjnej

  1. Molten J.E., Harvey J.W.: Tumors of lymphoid and hematopoietic tissue. [In:] Moulton J.E. (ed.): Tumors in Domestic Animals. 3rd ed. Berkeley, CA, University of California Press, 1990.
  2. Valli V.E., San Myint M., Barthel A. et al.: Classification of canine malignant lymphomas according to the World Health Organization criteria. „Vet Pathol”, 2011, 48 (1), 198-211.
  3. Withrow S.J., Vail D.M. (eds.): Withrow and McEwen’s Small Animal Clinical Oncology. 4th ed. Philadelphia, PA, Saunders-Elsevier, 2007.
  4. Modiano J.F., Breen M., Burnett R.C. et al.: Distinct B-cell and T-cell lymphoproliferative disease prevalence among dog breeds indicates heritable risk. „Cancer Res”, 2005, 65 (13), 5654-5661.
  5. Hoar S.K., Blair A., Holmes F.F. et al.: Agricultural herbicide use and risk of lymphoma and soft tissue sarcoma. „JAVMA”, 1986, 256 (9), 1141-1147.
  6. Weir E.C., Norrdin R.W., Matus R.E. et al.: Humoral hypercalcemia of malignancy in canine lymphosarcoma. „Endocrinology”, 1988, 122 (2), 602-608.
  7. Jagielski D., Lechowski R., Hoffmann-Jagielska M., Winiarczyk S.: Retrospective study of the incidence and prognostic factors of multicentric lymphoma in dogs (1998-2000). „J Vet Med A Physiol Pathol Clin Med”, 2002, 49 (8), 419-424.
  8. Mauldin G.E., Fox P.R., Patnaik A.K., Bond B.R., Mooney S.C., Matus R.E.: Doxorubicin-induced cardiotoxicosis. Clinical features in 32 dogs. „JVIM”, 1992, 6 (2), 82-88.
  9. MacEwen E.G., Brown N.O., Patnaik A.K., Passe S.: Cyclic combination chemotherapy of canine lymphosarcoma. „JAVMA”, 1981, 178 (11), 1178-1181.
  10. Vail D.M., Pinkerton M.E., Young K.M.: Hematopoietic tumors, canine lymphoma and lymphoid leukemia. [In:] Small Animal Clinical Oncology. 5th ed. St. Louis, MO, Elsevier Saunders, 2013, 608-638.
  11. Williams L.E.: Lymphoma, dog (multicentric). [In:] Côté E. (ed.): Clinical Veterinary Advisor: Dogs and Cats. 2nd ed. St. Louis, MO, Elsevier Mosby, 2011, 675-678.
  12. White C.R., Hohenhaus A.E., Kelsey J., Procter-Gray E.: Cutaneous MCTs: associations with spay/neuter status, breed, body size, and phylogenetic cluster. „J Am Anim Hosp Assoc”, 2011, 47 (3), 210-216.
  13. Thamm D.H., Vail D.M.: Mast cell tumors. [In:] Withrow S.J., Vail D.M., Page R.L. (eds.): Withrow and MacEwen’s Small Animal Clinical Oncology. 5th ed. St. Louis, MO, Elsevier Saunders, 2013, 335-349.
  14. Webster D.J., Yuzbasiyan-Gurkan V., Thamm S.H., Hamilton E., Kiupel M.: Evaluation of prognostic markers for anine mast cell tumors treated with vinblastine and prednisone. „BMC Veterinary Reasearch”, 4, Artcile Number: 32 (2008).
  15. Kiupel M., Webster J.D., Miller R.A., Kaneene J.B.: Impact of tumour depth, tumour location and multiple synchronous masses on the prognosis of canine cutaneous mast cell tumours. J „Vet Med A Physiol Pathol Clin Med”, 2005, 52 (6), 280-286.
  16. Seguin B., Leibman N.F., Bregazzi V.S., Ogilvie G.K., Powers B.E,. Dernell W.S., Fettman M.J., Withrow S.J.: Clinical outcome of dogs with grade-II mast cell tumors treated with surgery alone: 55 cases (1996-1999). „J Am Vet Med Assoc”, 2001, 218 (7), 1120-1123. 10.2460/javma.2001.218.1120.
  17. Thamm D.H., Mauldin E.A., Vail D.M.: Prednisone and vinblastine chemotherapy for canine mast cell tumor − 41 cases (1992-1997). „J Vet Intern Med”, 1999, 13 (5), 491-497. 10.1892/0891-6640(1999)013<0491:PAVCFC>2.3.CO;2.
  18. Boudrieau R.J., McCarthy R.J., Sisson R.D.: Sarcoma of the proximal portion of the tibia in a dog 5.5 years after tibial plateau leveling osteotomy. „JAVMA”, 2005, 227 (10), 1613-1617.
  19. Sartor A.J., Ryan S.D., Sellmeyer T., Withrow S.J., Selmic L.E.: Bi-institutional retrospective cohort study evaluating the incidence of osteosarcoma following tibial plateau levelling osteotomy (2000-2009). „Vet Comp Orthop Traumatol”, 2014, 27 (5), 339-345.
  20. Arthur E.G., Arthur G.L., Keeler M.R., Bryan J.N.: Risk of osteosarcoma in dogs after open fracture fixation. „Vet Surg”, 2016, 45 (1), 30-35.
  21. Ru G., Terracini B., Glickman L.T.: Host related risk factors for canine osteosarcoma. „Vet J”, 156 (1), 31-39, 1998.
  22. Cooley D.M., Beranek B.C., Schlittler D.L. et al.: Endogenous gonadal hormone exposure and bone sarcoma risk. „Cancer Epidemiol Biomarkers Prev”, 11 (11), 1434-1440, 2002.
  23. Wykes P.M., Withrow S.J., Powers B.E.: Closed biopsy for diagnosis of long bone tumors: Accuracy and results. „JAAHA”, 21, 489-494, 1985.
  24. Simon M.S.: Biopsy of musculoskeletal tumors. „J Bone Joint Surg Am”, 64, 1254-1257, 1982.
  25. Schick A.R., Hayes G.M., Singh A. et al.: Development and validation of a hemangiosarcoma likelihood prediction model in dogs presenting with spontaneous hemoabdomen: the HeLP score. „J Vet Emerg Crit Care (San Antonio)”, 2019, 29 (3), 239-245.
  26. Matsuyama A., Poirier V.J., Mantovani F., Foster R.A., Mutsaers A.J.: Adjuvant doxorubicin with or without metronomic cyclophosphamide for canine splenic hemangiosarcoma. „J Am Anim Hosp Assoc”, 2017, 53 (6), 304-312.
  27. Fosmire S.P., Dickerson E.B., Scott A.M. et al.: Canine malignant hemangiosarcoma as a model of primitive angiogenic endothelium. „Lab Invest”, 2004, 84 (5), 562-572.
  28. Clifford C.A., Mackin A.J., Henry C.J.: Treatment of canine hemangiosarcoma: 2000 and beyond. „J Vet Intern Med”, 2000, 14 (5), 479-485.
  29. Brown N.O., Patnaik A.K., MacEwen E.G.: Canine hemangiosarcoma: retrospective analysis of 104 cases. „J Am Vet Med Assoc”, 1985, 186 (1), 56-58.
  30. Day M.J., Lucke V.M., Pearson H.: A review of pathological diagnoses made from 87 canine splenic biopsies. „J Small Anim Pract”, 1995, 36 (10), 426-433.
  31. Wendelburg K.M., Price L.L., Burgess K.E., Lyons J.A., Lew F.H., Berg J.: Survival time of dogs with splenic hemangiosarcoma treated by splenectomy with or without adjuvant chemotherapy: 208 cases (2001-2012). „J Am Vet Med Assoc”, 2015, 247 (4), 393-403.
  32. Wiley J.L., Rook K.A., Clifford C.A., Gregor T.P., Sorenmo K.U.: Efficacy of doxorubicin-based chemotherapy for non-resectable canine subcutaneous haemangiosarcoma. „Vet Comp Oncol”, 2010, 8 (3), 221-233.
  33. Weisse C., Soares N., Beal M.W., Steffey M.A., Drobatz K.J., Henry C.J.: Survival times in dogs with right atrial hemangiosarcoma treated by means of surgical resection with or without adjuvant chemotherapy: 23 cases (1986-2000). „J Am Vet Med Assoc”, 2005, 226 (4), 575-579.
  34. Withrow S.J., Vail D.M.: Diagnostic imaging in oncology: Withrow & MacEwen’s Small Animal Clinical Oncology. 4th ed. St. Louis, Saunders, 2007, 97-111.
  35. Adams W., Kleiter M., Thrall D. et al.: Prognostic significance of tumor histology and computed tomographic staging for radiation treatment response of canine nasal tumors. „Vet Radiol Ultrasound”, 50, 330-335, 2009.
  36. MacEwen E.G., Withrow S.J., Patnaik A.K. Nasal tumors in the dog: retrospective evaluation of diagnosis, prognosis, and treatment. „J Am Vet Med Assoc”, 1977, 170, 45-48.
  37. Malinowski C.: Canine and feline nasal neoplasia. „Clin Tech Small Anim Pract”, 2006, 21, 89-94.
  38. Knapp D.W., Richardson R.C., Bonney P.L. et al.: Cisplatin therapy in 41 dogs with malignant tumors. „J Vet Intern Med”, 1988, 2, 41-46.
dr n. wet. Ewa Kautz
Katedra Chorób Dużych Zwierząt z Kliniką
Wydział Medycyny Weterynaryjnej
SGGW w Warszawie

Nowoursynowska 100 02-787 Warszawa

Znajdź swoją kategorię

2710 praktycznych artykułów - 324 ekspertów - 22 kategorii tematycznych

Weterynaria w Terenie

Poznaj nasze serwisy